euro adhoc: Sartorius AG
quarterly or semiannual financial statement
Group
sales revenue climbed 15.1%; currency-adjusted, up 12.5%
EBITDA improved 48.9%
to EUR16.4 million
EBIT up 80.2% to EUR11.7 million
Earnings per share:
EUR0.37 (Q1 of 200
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
20.04.2006
During the first three months of 2006, sales revenue of the Sartorius Group rose 15.1% (currency-adjusted: +12.5%) to EUR128.6 million (Q1 of 2005: EUR111.8 mn). Sales revenue for the Biotechnology Division climbed 15.8% (currency-adjusted: +13.2%) to EUR68.2 million (EUR58.9 mn). For the Mechatronics Division, sales revenue grew 14.3% (currency-adjusted: +11.7%) to EUR60.4 million (EUR52.9 mn). Up 15.8% (currency-adjusted: +12.8%) to EUR132.7 million (EUR114.6 mn), Group order intake also showed positive development (currency-adjusted for Biotechnology Division: +20.8%; currency-adjusted for Mechatronics Division: +5.2%).
Earnings before interest, taxes, depreciation and amortization (EBITDA) increased from EUR11.0 million to EUR16.4 million (+48.9%). EBIT, earnings before interest and taxes, soared 80.2% to EUR11.7 million (EUR6.5 mn). The EBIT margin improved from 5.8% to 9.1%. EBIT for the Biotechnology Division rose from EUR4.3 million to EUR7.3 million; that of the Mechatronics Division, from EUR2.2 million to EUR4.4 million. At EUR6.3 million, net profit for the period also substantially surpassed the year-earlier quarterly figure (EUR2.2 million); earnings per share were EUR0.37, up from EUR0.13 a year ago.
At EUR3.1 million (EUR8.1 mn), net cash flow was positive and primarily used to reduce net debt by EUR1.8 million to EUR58.9 million.
In comparison to the relatively moderate year-earlier quarter, sales revenue growth was above-average. For the full year, we further expect to increase sales revenue by more than 5% based on constant currencies and to post earnings before interest and taxes of approximately 10% of sales revenue.
end of announcement euro adhoc 20.04.2006 07:24:35
Further inquiry note:
Andreas Wiederhold
Phone +49.551.308.1668
andreas.wiederhold@sartorius.com
Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / official dealing/prime standard
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Bayerische Börse / free trade
Niedersächsische Börse zu Hannover / official dealing